epcoritamab
abbvie,genmab
['nhl', 'epcore,nhl,3', 'lymsm', 'lymphoma', 'epcore,nhl,2', 'epcoritamab']
congress #eha2022 | catherine thieblemont presented epcore-nhl-1 phase ii study results of epcoritamab in pts with r/r lbcl. n=157, median follow-up=10.7 months, orr=63%, cr=39%, low grade aes including crs #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm